Renaissance Group Lifted China Mobile LTD (CHL) Stake By $362,596; Rock Springs Capital Management LP Has Increased Ultragenyx Pharmaceutical In (RARE) Stake

August 26, 2017 - By Vivian Currie

Renaissance Group Llc increased China Mobile Ltd (CHL) stake by 3.01% reported in 2016Q4 SEC filing. Renaissance Group Llc acquired 6,973 shares as China Mobile Ltd (CHL)’s stock declined 1.23%. The Renaissance Group Llc holds 238,714 shares with $12.52 million value, up from 231,741 last quarter. China Mobile Ltd now has $230.72 billion valuation. The stock increased 0.30% or $0.17 on August 25, reaching $56.15. About 312,088 shares traded. China Mobile Ltd. (ADR) (NYSE:CHL) has risen 3.24% since August 26, 2016 and is uptrending. It has underperformed by 13.46% the S&P500.

Rock Springs Capital Management Lp increased Ultragenyx Pharmaceutical In (RARE) stake by 8.67% reported in 2016Q4 SEC filing. Rock Springs Capital Management Lp acquired 12,750 shares as Ultragenyx Pharmaceutical In (RARE)’s stock declined 25.28%. The Rock Springs Capital Management Lp holds 159,750 shares with $11.23 million value, up from 147,000 last quarter. Ultragenyx Pharmaceutical In now has $2.18B valuation. The stock decreased 0.06% or $0.03 on August 25, reaching $51.4. About 385,916 shares traded or 36.82% up from the average. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 6.49% since August 26, 2016 and is downtrending. It has underperformed by 23.19% the S&P500.

Among 5 analysts covering China Mobile (NYSE:CHL), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. China Mobile had 6 analyst reports since August 21, 2015 according to SRatingsIntel. Goldman Sachs maintained the shares of CHL in report on Wednesday, August 10 with “Buy” rating. The rating was maintained by Jefferies on Friday, August 21 with “Buy”. The stock has “Mkt Perform” rating by Bernstein on Thursday, October 27. The stock has “Hold” rating by HSBC on Friday, March 24. The rating was upgraded by Deutsche Bank on Tuesday, January 19 to “Buy”.

Renaissance Group Llc decreased Aetna Inc (NYSE:AET) stake by 8,513 shares to 256,700 valued at $31.83 million in 2016Q4. It also reduced Synopsys Inc (NASDAQ:SNPS) stake by 38,004 shares and now owns 542,556 shares. Magna International Inc (NYSE:MGA) was reduced too.

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.14, from 1.21 in 2016Q3. It worsened, as 17 investors sold RARE shares while 56 reduced holdings. 24 funds opened positions while 54 raised stakes. 40.89 million shares or 5.30% more from 38.83 million shares in 2016Q3 were reported. Blackrock Institutional Na has 0.01% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 1.05 million shares. Trexquant Investment Limited Partnership owns 3,600 shares or 0.04% of their US portfolio. Emerald Advisers Inc Pa holds 337,629 shares or 1.01% of its portfolio. Sg Americas Secs Lc has 0.01% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Maryland-based Clearbridge Ltd Limited Liability Company has invested 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Personal holds 3,790 shares. Putnam Investments Limited Liability Company invested in 85,583 shares or 0.01% of the stock. Proshare Advsrs Limited Liability Company invested 0.03% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Hsbc Public Ltd Company holds 8,645 shares or 0% of its portfolio. Opus Point Ptnrs Mngmt Lc owns 10,864 shares. Tower Rech Limited Liability Corp (Trc) holds 0% or 465 shares in its portfolio. Polar Limited Liability Partnership owns 331,220 shares for 0.37% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 2,348 shares. First Mercantile Trust holds 0.02% or 1,954 shares in its portfolio. Rockefeller Fincl Inc reported 379,761 shares stake.

Rock Springs Capital Management Lp decreased Biogen Inc (NASDAQ:BIIB) stake by 11,000 shares to 47,000 valued at $13.33 million in 2016Q4. It also reduced Gilead Sciences Inc (NASDAQ:GILD) stake by 67,500 shares and now owns 276,500 shares. Allergan Plc was reduced too.